BofA upgraded Imperial Brands to Buy from Neutral and set a GBP32.00 price target, reiterating confidence in FY26 EBIT growth of 3%–5% (BofA: 3.2% vs consensus). The firm expects upside into FY27 at 4.4% growth vs a 3.4% consensus, citing lapping one-offs, a moderating high-margin Australia drag, and ongoing cost savings. The stock is down ~13% since April and trades around 7.6x forward P/E (down from ~9x after the April 14 update), with the article’s fair-value model suggesting it is undervalued.
This is a valuation + earnings-quality setup, not a secular growth story. The near-term upside comes from a cleaner FY26/FY27 margin bridge as lapping effects and footprint actions reduce the need for promotional spend; if that bridge holds, the multiple can normalize before the market fully believes the volume line.
The bigger second-order risk is competitive escalation across nicotine categories. If larger rivals keep spending on price and pouches, Imperial can get squeezed in the middle: modest share loss at a lower-scale operator can offset several points of cost savings because the market will discount the terminal cash flow, not just the next quarter's EPS.
Contrarian take: the selloff may be pricing in a permanent share erosion narrative that is stronger than the current evidence supports. The thesis is falsified if FY26 guidance slips below the low end, priority-market share deterioration accelerates beyond roughly 10 bps, or operating savings are absorbed by incremental trade spend; if those hold, this can work as a 1-3 month re-rating trade with a 6-12 month cash-flow tailwind.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
